# Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00550836** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 104 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** panitumumab
- **DRUG:** erlotinib hydrochloride
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00550836
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-11
- **Final completion:** 2013-05
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550836, "Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00550836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*